RecruitingNCT06706570

PIK3CA Mutational Status Assessment

PIK3CA Mutational Status Assessment: Towards a "Tailored" Diagnostic Approach

Sponsor

European Institute of Oncology

Enrollment

100 participants

Start Date

Nov 6, 2024

Study Type

OBSERVATIONAL

Conditions

Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.

Sex: FEMALEMin Age: 18 Years

• Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory.
Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), or Silver-enhanced in situ hybridization (SISH)) test is required by local laboratory testing.
Participants should be at advanced or metastatic setting prior to treatment.
Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
Patients must be accessible for follow-up.

patients already treated with different treatments like chemotherapy, hormone therapy etc
\-

European Institute of Oncology

Milan, MI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06706570